UroGen Pharma Ltd.
URGNFigures shown here come from public SEC filings. Dates beside each section show the available history.
How UroGen Pharma Ltd. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 11 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 24, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Schonfeld Strategic Advisors LLC | 2026-03-31 | 158,111 | $2.84M | SEC filing |
| UBS Group AG | 2026-03-31 | 159,658 | $2.87M | SEC filing |
| True Wealth Design, LLC | 2026-03-31 | 16 | $288 | SEC filing |
| KBC Group NV | 2026-03-31 | 1,340 | Not shown | SEC filing |
| TORONTO DOMINION BANK | 2026-03-31 | 2,616,714 | $47M | SEC filing |
| MAI Capital Management | 2026-03-31 | 14,006 | $252K | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 523,831 | $9.42M | SEC filing |
| MEITAV INVESTMENT HOUSE LTD | 2026-03-31 | 22,223 | $400K | SEC filing |
| BENDER ROBERT & ASSOCIATES | 2026-03-31 | 34,701 | $624K | SEC filing |
| Jefferies Financial Group Inc. | 2026-03-31 | 2,199,652 | $39.5M | SEC filing |
| Advisory Services Network, LLC | 2026-03-31 | 553 | $9.94K | SEC filing |
| CWM, LLC | 2026-03-31 | 3,894 | $70K | SEC filing |
| NEW YORK STATE COMMON RETIREMENT FUND | 2026-03-31 | 12,737 | $229K | SEC filing |
| Soleus Capital Management, L.P. | 2026-03-31 | 727,000 | $13.1M | SEC filing |
| Optiver Holding B.V. | 2026-03-31 | 152 | $2.73K | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 275,938 | $4.96M | SEC filing |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 2026-03-31 | 387,074 | $6.96M | SEC filing |
| Annandale Capital, LLC | 2026-03-31 | 58,552 | Not shown | SEC filing |
| Napier Financial, LLC | 2026-03-31 | 400 | $7.19K | SEC filing |
| Pinnacle Wealth Planning Services, Inc. | 2026-03-31 | 688 | $12.4K | SEC filing |
- Each value is checked against UroGen Pharma Ltd.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 2 rows: the filed value is about 1,000 times too small for the share count at UroGen Pharma Ltd.'s share price.
120 filers have only one report here.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-22 | Schoenberg Mark · Chief Medical Officer | Ordinary Shares | S — Open market or private sale | −10,000 | 35.01 | SEC filing |
| 2026-06-08 | Schoenberg Mark · Chief Medical Officer | Ordinary Shares | S — Open market or private sale | −5,222 | 27.30 | SEC filing |
| 2026-05-08 | Schoenberg Mark · Chief Medical Officer | Ordinary Shares | S — Open market or private sale | −10,000 | 30.00 | SEC filing |
| 2026-02-03 | Smith Jason Drew · General Counsel | Ordinary Shares | S — Open market or private sale | −2,654 | 19.69 | SEC filing |
| 2026-02-03 | Schoenberg Mark · Chief Medical Officer | Ordinary Shares | S — Open market or private sale | −3,686 | 19.69 | SEC filing |
| 2026-02-03 | Schoenberg Mark · Chief Medical Officer | Ordinary Shares | S — Open market or private sale | −1,843 | 19.69 | SEC filing |
| 2026-02-03 | Schoenberg Mark · Chief Medical Officer | Ordinary Shares | S — Open market or private sale | −1,844 | 19.69 | SEC filing |
| 2026-02-03 | Smith Jason Drew · General Counsel | Ordinary Shares | S — Open market or private sale | −3,217 | 19.69 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-22 | Holden Stuart · Director | Stock Option (right ot buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-06-22 | Robinson James A. Jr. · Director | Restricted Stock Unit | A — Grant, award, or other acquisition | +8,000 | SEC filing |
| 2026-06-22 | WEN LEANA · Director | Stock Option (right ot buy) | A — Grant, award, or other acquisition | +10,000 | SEC filing |
| 2026-06-22 | BUTITTA CYNTHIA M · Director | Stock Option (right ot buy) | A — Grant, award, or other acquisition | +10,000 | SEC filing |
| 2026-06-22 | Belldegrun Arie · Director | Stock Option (right ot buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-06-22 | Wildman Daniel George · Director | Stock Option (right ot buy) | A — Grant, award, or other acquisition | +10,000 | SEC filing |
| 2026-06-22 | WEN LEANA · Director | Restricted Stock Unit | A — Grant, award, or other acquisition | +8,000 | SEC filing |
| 2026-06-22 | Robinson James A. Jr. · Director | Stock Option (right ot buy) | A — Grant, award, or other acquisition | +10,000 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.